Best Cell & Gene Therapy CDMOs in Europe
Cell & Gene Therapy manufacturers on CDMO Signal: 43 listed with manufacturing sites in Europe. 8 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Novartis (in-house manufacturer, Signal Score 85.4), Takeda (also makes its own products, Signal Score 83.4) and Merck KGaA / MilliporeSigma (CDMO) (also makes its own products, Signal Score 81.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Charles River Laboratories (Signal Score 86.3) and Minaris Advanced Therapies (Signal Score 83.1). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Cell & Gene Therapy CDMOs in Europe with the most regulatory evidence on file
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 33 NAI (no action), 37 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (52), United States (45), UNITED KINGDOM (45), Austria (39), Germany (28).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 2 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 3 |
|
85.4 | 97.4 | 17 insp · 51 GMP | 2026-06-24 · NAI | — | 135 programs |
| 4 |
TK
|
83.4 | 100.0 | 4 insp · 20 GMP | 2026-04-10 · NAI | — | 100 programs |
| 5 |
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.1 | 99.2 | 3 insp · 4 GMP | 2025-11-25 · NAI | Limited | — |
| 6 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 7 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 8 |
SC
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | None on file | — | — |
| 9 |
EF
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 7 insp · 0 GMP | 2026-05-15 · NAI | — | — |
| 10 |
CF
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 11 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 12 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 13 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 14 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 15 |
RC
|
79.3 | 96.8 | 1 insp · 1 GMP | 2025-01-21 · VAI | Available | — |
| 16 |
AA
Rockville, MD · Alachua, FL · Munich, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 17 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 18 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 19 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 20 |
CE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 21 |
XP
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 22 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 23 |
VG
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | Available | — |
| 24 |
SY
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 8 GMP | 2025-01-31 · NAI | — | — |
| 25 |
CY
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 26 |
CN
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 27 |
HH
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 28 |
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
|
76.2 | 100.0 | 2 insp · 13 GMP | 2024-06-17 · NAI | Available | 7 programs |
| 29 |
MB
|
73.0 | 100.0 | 0 insp · 2 GMP | None on file | — | 8 programs |
| 30 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 31 |
RT
|
71.1 | 100.0 | 0 insp · 4 GMP | None on file | — | 1 program |
| 32 |
CG
|
65.5 | — | — | None on file | — | — |
| 33 |
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
|
64.0 | — | — | None on file | — | — |
| 34 |
RA
Stockholm, Sweden
|
63.0 | — | — | None on file | — | — |
| 35 |
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
|
61.8 | — | — | None on file | — | 10 programs |
| 36 |
OR
|
59.0 | — | — | None on file | — | — |
| 37 |
CP
|
59.0 | — | — | None on file | — | — |
| 38 |
EX
|
59.0 | — | — | None on file | — | — |
| 39 |
CZ
Cologne, Germany
|
59.0 | — | — | None on file | — | — |
| 40 |
AM
Gerenzano, Italy
|
59.0 | — | — | None on file | — | — |
| 41 |
CV
Cologne, Germany
|
56.5 | — | — | None on file | — | — |
| 42 |
CX
|
56.5 | — | — | None on file | — | — |
| — |
Germany
|
Profiled | — | 2 insp · 2 GMP | 2023-09-08 · VAI | — | — |
What to evaluate in a Cell & Gene Therapy CDMO
EMA and MHRA regulatory considerations for European-manufactured programs
QP release requirements and how they affect CDMO selection
Which European CDMOs also cover FDA (US) regulatory geography?
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Best cell and gene therapy CDMO in Europe
Cell therapy and gene therapy manufacturers with European facilities, ranked together.